Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Sodium-glucose co-transporter 2 inhibitors might enhance erythropoiesis and increase red blood cell mass. We assessed the effects of canagliflozin versus matched placebo on hemoglobin and hematocrit using linear mixed-effects models. The risk of the composite outcome of anemia events or the initiation of treatment for anemia was lower in the theCanag liflonzin group.
